Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA

Key Points

• Algert Global increased its Savara stake by 53.7% in the second quarter, purchasing 464,645 additional shares and bringing its holdings to 1.33 million shares worth approximately $8.2 million.
• Institutional ownership remains high at 87.93%, with major investors including VR Adviser, BlackRock, Vanguard, Nantahala Capital Management and Polar Capital also holding significant positions.
• Savara reported a quarterly loss of $0.16 per share, missing estimates by $0.02. Analysts maintain a consensus “Moderate Buy” rating with a $10.14 price target, despite some sell ratings.

Algert Global LLC boosted its position in Savara Inc. (NASDAQ:SVRA - Free Report) by 53.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,329,259 shares of the company's stock after purchasing an additional 464,645 shares during the quarter. Algert Global LLC owned about 0.65% of Savara worth $8,188,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. VR Adviser LLC boosted its position in shares of Savara by 8.4% during the 4th quarter. VR Adviser LLC now owns 13,740,375 shares of the company's stock valued at $82,854,000 after acquiring an additional 1,059,332 shares during the last quarter. BlackRock Inc. bought a new position in shares of Savara in the 2nd quarter worth $76,966,000. Vanguard Group Inc. increased its stake in Savara by 20.8% in the fourth quarter. Vanguard Group Inc. now owns 10,041,647 shares of the company's stock valued at $60,551,000 after acquiring an additional 1,728,453 shares during the last quarter. Nantahala Capital Management LLC increased its stake in Savara by 5.4% in the third quarter. Nantahala Capital Management LLC now owns 8,775,375 shares of the company's stock valued at $31,328,000 after acquiring an additional 450,000 shares during the last quarter. Finally, Polar Capital Holdings Plc purchased a new stake in Savara during the fourth quarter valued at about $50,086,000. 87.93% of the stock is owned by institutional investors.

Savara Stock Performance

Shares of Savara stock opened at $5.61 on Thursday. The company has a current ratio of 10.13, a quick ratio of 10.13 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $1.15 billion, a P/E ratio of -9.67 and a beta of 0.29. The business has a fifty day simple moving average of $5.71 and a two-hundred day simple moving average of $5.48. Savara Inc. has a 12 month low of $3.19 and a 12 month high of $7.01.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). On average, equities analysts forecast that Savara Inc. will post -0.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Wall Street Zen cut Savara from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $10.14.

Savara Profile

Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source